Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.

Niels PorksenHelle LinnebjergParag GarhyanEric C Q LamMary P KnadlerScott J JacoberUlrike HoevelmannLeona Plum-MoerschelElaine WatkinsFrancesco RubinoTim Heise

Published in: Diabetes, obesity & metabolism (2017)

The need to reduce prandial insulin observed with BIL during phase 3 trials cannot be explained by the differential effects of BIL and GL on sensitivity to prandial insulin in either T1DM or T2DM.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
weight loss
metabolic syndrome